A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma (Q36082501)

12 August 2017

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma (English)

1 reference

12 August 2017

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

7

Jeffrey J Olson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

10

Patrick Y Wen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

11

Rakesh K Jain

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

5

Tom Mikkelsen

1 reference

12 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

2

Xiaobu Ye

1 reference

12 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12

Tracy T Batchelor

1 reference

12 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

Elizabeth R Gerstner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Dan G Duda

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Michael A Levine

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Burt L Nabors

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Manmeet S Ahluwalia

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Stuart Grossman

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

24 May 2015

1 reference

12 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

1386-1392

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

12 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Molecular mechanisms and clinical applications of angiogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Modes of resistance to anti-angiogenic therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

High-dose antiangiogenic therapy for glioblastoma: less may be more?

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4578584

23 September 2018

Identifiers

DOI

10.1093/NEUONC/NOV085

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26008604%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

PubMed publication ID

26008604

1 reference